Bortezomib 179324-69-7

• Post Date:

  May 07,2019

• Expiry Date:

  Nov 03,2019

• Detailed Description:

  Cas No. :179324-69-7 Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.

• CAS Registry Number:

  179324-69-7

• Synonyms:

  ;VELCADE;dpba;[(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid;VELCADE(BORTEZOMIB);Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-;Bortezomib for research;N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide;N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide;Bortizomib;

• Molecular Formula:

  C₁₉H₂₅BN₄O₄

• Molecular Weight:

  384.2372

• Molecular Structure:

  

• Company:

  Shanghai Neopharm Co., Ltd.     [ China ]          

• Contact:

  Carol Zhu

• Tel:

  021-58826758

• Fax:

  021-58827258

• Email:

  sales@neopharm.com.cn